Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV-SHIELD trial of clesrovimab in infants
2026-526874-18-00Phase 4Authorised
- Sponsor
- University of Crete
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Fexinidazole in respiratory syncytial virus disease (RSV) (2 arms), sponsored by University of Crete. Primary endpoints: RSV nasopharyngeal detection and shedding, Non-RSV respiratory pathogen carriage and clearance and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
Fexinidazole
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2026-526874-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526874-18-00.